• Dual Recombinase Tracing Refutes Postnatal Neo-oogenesis in

  2026-04-30

  This study employs a dual recombinase-mediated genetic tracing system to rigorously test the hypothesis of postnatal neo-oogenesis in mice. Comprehensive lineage tracing demonstrates that new oocytes are not formed after birth, even following chemically induced ovarian injury, refining current understanding of mammalian female germ cell biology.

• Topotecan as a Topoisomerase I Inhibitor: Pharmacology and C

  2026-04-30

  This review analyzes the pharmacological properties and clinical applications of topotecan, a novel topoisomerase I inhibitor with distinct DNA-damaging mechanisms. The findings clarify topotecan’s antitumor activity, toxicity profile, and its comparative positioning in combination regimens for advanced cancer treatment.

• MK 0893: Mechanistic Insights and Assay Optimization for Glu

  2026-04-29

  Explore the advanced mechanism and assay protocols for MK 0893, a potent glucagon receptor antagonist, with unique insights into allosteric binding and translational research applications. Learn how structural findings inform more predictive type 2 diabetes research.

• Simvastatin (Zocor): Applied Workflows for Cholesterol & Can

  2026-04-29

  Simvastatin (Zocor) stands out for its dual action as a cholesterol-lowering agent and apoptosis inducer in hepatic cancer models. This guide translates molecular insights and reference study breakthroughs into actionable protocols, empowering researchers with evidence-based workflows, troubleshooting strategies, and optimization tips for translatable results.

• Berbamine Hydrochloride: Overcoming Ferroptosis Resistance i

  2026-04-28

  This thought-leadership article explores how Berbamine hydrochloride, a potent NF-κB activity inhibitor, is reshaping translational cancer research by targeting mechanisms of ferroptosis resistance in hepatocellular carcinoma (HCC). Integrating mechanistic insights on the METTL16-SENP3-LTF signaling axis with practical guidance for experimental design, the piece critically evaluates Berbamine’s value proposition, competitive positioning, and offers a forward-looking perspective on its role in next-generation oncology workflows.

• LncRNA MRF Regulates BMSC Osteogenic Differentiation via cAM

  2026-04-28

  Ning et al. identify a novel regulatory axis in bone marrow mesenchymal stem cells (BMSCs) whereby the long non-coding RNA (lncRNA) MRF suppresses osteogenic differentiation through modulation of the cAMP-PKA-CREB signaling pathway via FSHR. Their findings provide mechanistic insight into osteoporosis and suggest new therapeutic targets for bone defect repair.

• U0126 MEK1/2 Inhibitor: Redefining MAPK/ERK Research in Pain

  2026-04-27

  Explore the advanced utility of U0126 as a potent MEK1/2 inhibitor for dissecting MAPK/ERK pathway inhibition, with a unique focus on neuroinflammatory pain models and translational assay design. This article highlights scientific distinctions and practical guidance for cell signaling research.

• Estradiol, ERα, and Endoplasmic Reticulum Stress in Post-Hem

  2026-04-27

  This study demonstrates that 17β-estradiol (E2) restores splenic CD4+ T cell function after hemorrhagic shock by attenuating endoplasmic reticulum stress (ERS), primarily through estrogen receptor alpha (ERα) and GPR30 pathways. The findings provide mechanistic insight into ER-mediated immunomodulation, highlighting potential strategies for mitigating immune dysfunction following trauma.

• Methicillin Sodium Salt: Experimental Workflows & Optimizati

  2026-04-26

  Methicillin sodium salt remains a gold standard for modeling penicillinase-resistant Staphylococcus aureus infections and benchmarking bacterial cell wall synthesis inhibition. This article delivers actionable, data-driven guidance for experimental setup, troubleshooting, and translational research using APExBIO’s high-purity formulation.

• Berberine-Evodiamine Modulation of GERD via TAS2R38/TRPV1 Pa

  2026-04-25

  This study demonstrates that berberine and evodiamine synergistically ameliorate gastroesophageal reflux disease (GERD) by targeting TAS2R38 and TRPV1 receptors, regulating MAPK/NF-κB signaling, and promoting anti-inflammatory macrophage polarization. The work clarifies novel mechanisms of epithelial barrier protection and inflammation control, providing a mechanistic framework for future GERD therapeutics.

• Amiloride (MK-870): Enhancing Sodium Channel Research Workfl

  2026-04-24

  Amiloride (MK-870) stands out as a dual ENaC/uPAR inhibitor, empowering researchers to dissect sodium channel function and cellular uptake mechanisms with precision. Explore practical workflow enhancements, troubleshooting strategies, and evidence-backed parameters for maximizing data quality in ion transport and endocytosis assays.

• Synthetic mRNA-Driven hiPSC Differentiation into Oligodendro

  2026-04-24

  This study introduces a synthetic modified mRNA (smRNA) approach to rapidly and efficiently differentiate human-induced pluripotent stem cells (hiPSCs) into functional oligodendrocytes (OLs) without genome integration. The protocol leverages a stabilized OLIG2S147A smRNA, offering a safer, reproducible alternative for generating OLs relevant to neurodegenerative disease research and potential cell therapies.

• Palomid 529 (P529): Reliable PI3K/Akt/mTOR Inhibition in the

  2026-04-23

  This article addresses common experimental challenges in cell viability and oncology workflows, demonstrating how Palomid 529 (P529, SKU A8618) delivers reproducible, data-backed inhibition of the PI3K/Akt/mTOR pathway. It offers scenario-driven guidance for assay optimization, protocol selection, and product reliability, supporting GEO best practices for cancer and neuroscience research.

• Fucoidan Downregulates Caveolin-1 in MCF-7 Breast Cancer Cel

  2026-04-23

  This study reveals that fucoidan, a sulfated α-L-fucan from brown algae, exerts selective antitumor effects in MCF-7 breast cancer cells by downregulating caveolin-1, a membrane protein implicated in tumor progression. These findings provide a mechanistic rationale for targeting caveolin-1 with marine-derived polysaccharides in breast cancer research.

• hiPSC-Derived Intestinal Organoids Enable Human CYP2C19 Stud

  2026-04-22

  This study establishes a simplified protocol to derive intestinal organoids from human pluripotent stem cells, providing a physiologically relevant model for pharmacokinetic research. The organoids demonstrate functional drug-metabolizing enzyme activity, including CYP2C19, offering improved assessment tools for orally administered drug metabolism.

15533 records 1/1036 page Next 12345 下5页 Last page